Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In acute crises such as the COVID-19 pandemic, scientific questions need to be addressed quickly in order to protect the health of the population and to maintain the function of the healthcare system. The prevailing urgency and the large number of issues to be addressed, combined with the limitation of time, personnel, or monetary resources make prioritization indispensable. In the COVID-19 Evidence Ecosystem (CEOsys) project initiated by the University Medicine Network (NUM), a procedure for the rapid prioritization of questions was used specifically for evidence syntheses and clinical guideline recommendations, which was further developed in the follow-up project PREparedness and Pandemic Response in Germany (PREPARED).The result is a concept paper on the prioritization of research questions and topics with a more generic orientation. The content of the concept is presented in this article. The core subjects are basic principles of successful prioritization as well as an explicit seven-step process with information on organizational framework conditions and the procedure. The concept offers possibilities for adaptation, as research prioritization is highly context-dependent.The application of such a systematic, transparent prioritization process contributes to comprehensible and informed decisions about which research questions are relevant and urgent, in which order they should be processed, and which issues are not critically urgent or have to be postponed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732861PMC
http://dx.doi.org/10.1007/s00103-024-03985-4DOI Listing

Publication Analysis

Top Keywords

prioritization questions
8
prioritization
6
[prioritization questions
4
questions health
4
health crises-presentation
4
crises-presentation a concept
4
a concept developed
4
developed covid-19
4
covid-19 pandemic]
4
pandemic] acute
4

Similar Publications

Monoclonal antibodies (mAb) have transformed modern medicine, offering targeted therapies for cancer, autoimmune disorders, and infectious diseases. To enhance patient convenience, subcutaneous administration is increasingly prioritized, requiring highly concentrated formulations. However, high viscosity of these formulations hinders manufacturability, injectability, and stability.

View Article and Find Full Text PDF

As the global protected area (PA) network expands to meet international targets, it is important to assess whether traditional reliance on public land will suffice for projected PA growth or whether other tenures, such as Indigenous or pastoral lands, may increasingly contribute. Another consideration is whether the relative importance of different tenures varies depending on the specific goals of the PA network. We used the mammal fauna of the Australian monsoon tropics (AMT), one of the world's largest intact tropical savannas, as a case study to address these questions.

View Article and Find Full Text PDF

Background: Conventional weed risk assessments (WRAs) are time-consuming and often constrained by species-specific data gaps. We present a validated, algorithmic alternative, the model, that integrates climatic suitability ( ), weed-related publication frequency (P) and global occurrence data ( ), using publicly available databases and artificial intelligence (AI)-assisted text screening with a large language model (LLM).

Results: The model was tested against independent weed hazard classifications for New Zealand and California.

View Article and Find Full Text PDF

Background: In pediatric intensive care units, pain, sedation, delirium, and iatrogenic withdrawal syndrome (IWS) must be managed as interrelated conditions. Although clinical practice guidelines (CPGs) exist, new evidence needs to be incorporated, gaps in recommendations addressed, and recommendations adapted to the European context.

Objective: This protocol describes the development of the first patient- and family-informed European guideline for managing pain, sedation, delirium, and IWS by the European Society of Paediatric and Neonatal Intensive Care.

View Article and Find Full Text PDF

Background: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) portends a devastating prognosis for patients, with survival typically being < 5 to 8 years after diagnosis. Limited clinical trial data exist to guide treatment strategies, and the efficacy of current strategies-immunomodulation and antifibrotics-remains uncertain. Large randomized controlled trials are costly, but pragmatic trial designs could reduce expenses.

View Article and Find Full Text PDF